The present disclosure relates to compounds that activate the mutant form of p53 protein to its wild-type form. The present disclosure also relates to a process of synthesis of the compounds and activation of the mutant p53 protein to its wild-type form by the compounds. Most human cancers harbour the p53 mutant protein and thus the compounds of the present disclosure display anti-cancer activity.